Advertisement

Virchows Archiv

, Volume 462, Issue 5, pp 565–574 | Cite as

Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas

  • Anne-Katrin ZimmermannEmail author
  • Jochen Imig
  • Agnes Klar
  • Christoph Renner
  • Dimitri Korol
  • Daniel Fink
  • Sylvia Stadlmann
  • Gad Singer
  • Alexander Knuth
  • Holger Moch
  • Rosmarie Caduff
Original Article

Abstract

MAGE-C1/CT7, NY-ESO-1, GAGE and MAGE-A4 are members of the cancer/testis (CT) antigen family, which have been proposed as potential targets for cancer immunotherapy. To determine the prevalence and biologic relevance of the novel CT antigen MAGE-C1/CT7 and other antigens, 36 ovarian borderline tumours (BTs), 230 primary ovarian carcinomas (OCs) and 80 recurrent OCs were immunohistochemically analysed using the monoclonal antibodies CT7-33 (MAGE-C1/CT7), E978 (NY-ESO-1), clone 26 (GAGE) and 57B (MAGE-A4). Positivity of at least one CT antigen was present in 39.5 % (81/205) of primary OC and in 50 % (26/52) of all recurrences. Expression of the novel CT antigen MAGE-C1/CT7 was most commonly seen with positivity in 24.5 % of primary and 35.1 % of recurrent OC. MAGE-A4, GAGE and NY-ESO-1 expressions were seen in 22.7, 13.9 and 7.1 % of primary and 22.6, 17.5 and 8.9 % of recurrent OC, respectively. Analysis of histological subtypes (serous, endometrioid, clear cell, mucinous and transitional) exhibited variable expression with negativity in all mucinous OC. High-grade serous OC revealed CT antigen expression in 5.6 to 28 % with MAGE-C1/CT7 being the most frequent, but without correlation with stage or overall survival. MAGE-C1/CT7 expression and coexpression of CT antigens were significantly correlated with grade of endometrioid OC. None of the BT showed CT antigen expression. No significant correlation was seen with stage, overall survival or response to chemotherapy. In summary, CT antigens are expressed in a certain subset of OC with no expression in BT or OC of mucinous histology. These findings may have implications for the design of polyvalent vaccination strategies for ovarian carcinomas.

Keywords

NY-ESO-1 MAGE-C1 GAGE CT7 Ovarian tumour Cancer/testis antigens 

Notes

Acknowledgments

The authors thank Martina Storz and Silvia Behnke for their excellent technical assistance. This work was supported by the Cancer Research Institute and the Zurich Cancer League (Zurich).

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics statement

The project was approved by the local ethics review boards of Bale and Zurich (Kantonale Ethikkomission Zurich, StV 27–2009). The aim of this retrospective study was immunohistochemical analysis of tumour tissue of patients with ovarian neoplasias (carinomas and borderline tumours). We tried to find a tissue marker that gives evidence for biologic behaviour (prognostic marker, good/bad prognosis) or can possibly be used as therapeutic targets for immunotherapies (therapeutic markers).

All tissue samples were taken from the archives after diagnostic processes were completed. Samples (186) were retrieved from the archives of the Institute for Surgical Pathology, University Hospital Zurich, Switzerland, covering the period from 1995 to 2005. Tissue samples of further 80 patients were available from the Institutes of Pathology, University Hospital Bale, Cantonal Hospital St. Gallen, Cantonal Hospital Baden and Cantonal Hospital Liestal from the period between 1985 and 2003.

According to the ethical rules of our local ethics committee, patient data were pseudoanonymised with patient identification numbers. To our knowledge, the results of this study have no influence on patient’s treatment (yet). However, should our results be of importance for the therapy of individual patients, they can again be identified.

In agreement with the local ethics committee, informed consent of individual patients was not obtained. Most patients of the collective examined are already dead. Thus, we relinquished to get patient consent or consent of family members in order not to upset them.

References

  1. 1.
    Heintz AP, Odicino F, Maisonneuve P et al (2003) Carcinoma of the ovary. Int J Gynaecol Obstet 83(Suppl 1):135–166PubMedCrossRefGoogle Scholar
  2. 2.
    Odunsi K, Sabbatini P (2008) Harnessing the immune system for ovarian cancer therapy. Am J Reprod Immunol 59:62–74PubMedCrossRefGoogle Scholar
  3. 3.
    Kandalaft LE, Powell DJ Jr, Singh N et al (2011) Immunotherapy for ovarian cancer: what's next? J Clin Oncol 29:925–933PubMedCrossRefGoogle Scholar
  4. 4.
    Simpson AJ, Caballero OL, Jungbluth A et al (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5:615–625PubMedCrossRefGoogle Scholar
  5. 5.
    Caballero OL, Chen YT (2009) Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 100:2014–2021PubMedCrossRefGoogle Scholar
  6. 6.
    Brasseur F, Rimoldi D, Lienard D et al (1995) Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 63:375–380PubMedCrossRefGoogle Scholar
  7. 7.
    Kocher T, Zheng M, Bolli M et al (2002) Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. Int J Cancer 100:702–705PubMedCrossRefGoogle Scholar
  8. 8.
    Kurashige T, Noguchi Y, Saika T et al (2001) Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res 61:4671–4674PubMedGoogle Scholar
  9. 9.
    Patard JJ, Brasseur F, Gil-Diez S et al (1995) Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int J Cancer 64:60–64PubMedCrossRefGoogle Scholar
  10. 10.
    van Baren N, Brasseur F, Godelaine D et al (1999) Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 94:1156–1164PubMedGoogle Scholar
  11. 11.
    Davis ID, Chen W, Jackson H et al (2004) Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A 101:10697–10702PubMedCrossRefGoogle Scholar
  12. 12.
    Jager D, Jager E, Knuth A (2001) Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol 54:669–674PubMedCrossRefGoogle Scholar
  13. 13.
    Jager D, Jager E, Knuth A (2001) Vaccination for malignant melanoma: recent developments. Oncology 60:1–7PubMedCrossRefGoogle Scholar
  14. 14.
    Jager E, Karbach J, Gnjatic S et al (2006) Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A 103:14453–14458PubMedCrossRefGoogle Scholar
  15. 15.
    Sadanaga N, Nagashima H, Mashino K et al (2001) Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 7:2277–2284PubMedGoogle Scholar
  16. 16.
    Scanlan MJ, Simpson AJ, Old LJ (2004) The cancer/testis genes: review, standardization, and commentary. Cancer Immun 4:1PubMedGoogle Scholar
  17. 17.
    Gillespie AM, Rodgers S, Wilson AP et al (1998) MAGE, BAGE and GAGE: tumour antigen expression in benign and malignant ovarian tissue. Br J Cancer 78:816–821PubMedCrossRefGoogle Scholar
  18. 18.
    Russo V, Dalerba P, Ricci A et al (1996) MAGE BAGE and GAGE genes expression in fresh epithelial ovarian carcinomas. Int J Cancer 67:457–460PubMedCrossRefGoogle Scholar
  19. 19.
    Yamada A, Kataoka A, Shichijo S et al (1995) Expression of MAGE-1, MAGE-2, MAGE-3/-6 and MAGE-4a/-4b genes in ovarian tumors. Int J Cancer 64:388–393PubMedCrossRefGoogle Scholar
  20. 20.
    Duan Z, Duan Y, Lamendola DE et al (2003) Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res 9:2778–2785PubMedGoogle Scholar
  21. 21.
    Egland KA, Kumar V, Duray P et al (2002) Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancers. Mol Cancer Ther 1:441–450PubMedGoogle Scholar
  22. 22.
    Tammela J, Uenaka A, Ono T et al (2006) OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. Int J Oncol 29:903–910PubMedGoogle Scholar
  23. 23.
    Straughn JM Jr, Shaw DR, Guerrero A et al (2004) Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer 108:805–811PubMedCrossRefGoogle Scholar
  24. 24.
    Tammela J, Jungbluth AA, Qian F et al (2004) SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer. Cancer Immun 4:10PubMedGoogle Scholar
  25. 25.
    Tureci O, Sahin U, Zwick C et al (1998) Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc Natl Acad Sci U S A 95:5211–5216PubMedCrossRefGoogle Scholar
  26. 26.
    Valmori D, Qian F, Ayyoub M et al (2006) Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells. Clin Cancer Res 12:398–404PubMedCrossRefGoogle Scholar
  27. 27.
    Chen YT, Gure AO, Tsang S et al (1998) Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci U S A 95:6919–6923PubMedCrossRefGoogle Scholar
  28. 28.
    Odunsi K, Jungbluth AA, Stockert E et al (2003) NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 63:6076–6083PubMedGoogle Scholar
  29. 29.
    Yakirevich E, Sabo E, Lavie O et al (2003) Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin Cancer Res 9:6453–6460PubMedGoogle Scholar
  30. 30.
    Leffers N, Daemen T, Helfrich W et al (2010) Antigen-specific active immunotherapy for ovarian cancer. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD007287.pub2 PubMedGoogle Scholar
  31. 31.
    Liu B, Nash J, Runowicz C et al (2010) Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol 3:7. doi: 10.1186/1756-8722-3-7
  32. 32.
    Gjerstorff MF, Johansen LE, Nielsen O et al (2006) Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy. Br J Cancer 94:1864–1873PubMedCrossRefGoogle Scholar
  33. 33.
    Cioca DP, Deak E, Cioca F et al (2006) Monoclonal antibodies targeted against melanoma and ovarian tumors enhance dendritic cell-mediated cross-presentation of tumor-associated antigens and efficiently cross-prime CD8+ T cells. J Immunother 29:41–52PubMedCrossRefGoogle Scholar
  34. 34.
    Bolli M, Kocher T, Adamina M et al (2002) Tissue microarray evaluation of melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg 236:785–793, discussion 793PubMedCrossRefGoogle Scholar
  35. 35.
    Sato E, Olson SH, Ahn J et al (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102:18538–18543PubMedCrossRefGoogle Scholar
  36. 36.
    Gure AO, Stockert E, Arden KC et al (2000) CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis. Int J Cancer 85:726–732PubMedCrossRefGoogle Scholar
  37. 37.
    Jungbluth AA, Chen YT, Busam KJ et al (2002) CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues. Int J Cancer 99:839–845PubMedCrossRefGoogle Scholar
  38. 38.
    Noske A, Zimmermann AK, Caduff R et al (2011) Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer. Virchows Arch 459:91–97PubMedCrossRefGoogle Scholar
  39. 39.
    Silverberg SG (2000) Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 19:7–15PubMedCrossRefGoogle Scholar
  40. 40.
    Malpica A (2008) Grading of ovarian cancer: a histotype-specific approach. Int J Gynecol Pathol 27:175–181PubMedGoogle Scholar
  41. 41.
    Stadlmann S, Gueth U, Reiser U et al (2006) Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Mod Pathol 19:607–610PubMedCrossRefGoogle Scholar
  42. 42.
    Stadlmann S, Gueth U, Wight E et al (2007) Expression of peroxisome proliferator activated receptor gamma and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma. J Clin Pathol 60:307–310PubMedCrossRefGoogle Scholar
  43. 43.
    Fossa A, Berner A, Fossa SD et al (2004) NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate 59:440–447PubMedCrossRefGoogle Scholar
  44. 44.
    Lendvai N, Gnjatic S, Ritter E et al (2010) Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. Cancer Immun 10:4PubMedGoogle Scholar
  45. 45.
    Stockert E, Jager E, Chen YT et al (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187:1349–1354PubMedCrossRefGoogle Scholar
  46. 46.
    Curioni-Fontecedro A, Knights AJ, Tinguely M et al (2008) MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma. Leukemia 22:1646–1648PubMedCrossRefGoogle Scholar
  47. 47.
    Zhang S, Zhou X, Yu H et al (2010) Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer 10:163PubMedCrossRefGoogle Scholar
  48. 48.
    Cheever MA, Allison JP, Ferris AS et al (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323–5337PubMedCrossRefGoogle Scholar
  49. 49.
    Jungbluth AA, Chen YT, Stockert E et al (2001) Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 92:856–860PubMedCrossRefGoogle Scholar
  50. 50.
    Fujita S, Wada H, Jungbluth AA et al (2004) NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin Cancer Res 10:6551–6558PubMedCrossRefGoogle Scholar
  51. 51.
    Vaughan HA, Svobodova S, Macgregor D et al (2004) Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res 10:8396–8404PubMedCrossRefGoogle Scholar
  52. 52.
    Harrison ML, Jameson C, Gore ME (2008) Mucinous ovarian cancer. Int J Gynecol Cancer 18:209–214PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Anne-Katrin Zimmermann
    • 1
    Email author
  • Jochen Imig
    • 2
  • Agnes Klar
    • 3
  • Christoph Renner
    • 4
  • Dimitri Korol
    • 5
  • Daniel Fink
    • 6
  • Sylvia Stadlmann
    • 7
  • Gad Singer
    • 7
  • Alexander Knuth
    • 8
  • Holger Moch
    • 1
  • Rosmarie Caduff
    • 1
  1. 1.Institute of Surgical PathologyUniversity Hospital ZurichZurichSwitzerland
  2. 2.Institute of Pharmaceutical ScienceETH ZurichZurichSwitzerland
  3. 3.Tissue Biology Research Unit, Department of SurgeryUniversity Children’s HospitalZurichSwitzerland
  4. 4.Onkozentrum Hirslanden ZürichKlinik HirslandenZurichSwitzerland
  5. 5.Institute of Social and Preventive MedicineUniversity of ZurichZurichSwitzerland
  6. 6.Department of GynecologyUniversity Hospital ZurichZurichSwitzerland
  7. 7.Institute of PathologyKantonsspital Baden AGBadenSwitzerland
  8. 8.Clinic of OncologyUniversity Hospital ZurichZurichSwitzerland

Personalised recommendations